Massachusetts Alzheimer's Disease Research Center

马萨诸塞州阿尔茨海默病研究中心

• 批准号: 9041267
• 负责人: BRADLEY T. HYMAN
• 金额: $ 20万
• 依托单位: MASSACHUSETTS GENERAL HOSPITAL
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-04-01 至 2019-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9041267
• 关键词: Alzheimer' s Disease; Animal Model; Biological; Brain; Caring; Clinical; Clinical Data; Cognition Disorders; Cognitive aging; Collaborations; Communities; Computer software; DNA; Databases; Dementia; Development; Discipline; Disease; Early Intervention; Education; Educational process of instructing; Elements; Environment; Functional Magnetic Resonance Imaging; Funding; Future; General Hospitals; Generations; Geriatric Psychiatry; Goals; Grant; Health; Hospitals; Human; Image; Impaired cognition; Individual; Institution; Intervention; Laboratories; Laboratory Study; Leadership; Learning; Magnetic Resonance Imaging; Massachusetts; Medical Students; Mentors; Methodology; Mission; Neurofibrillary Tangles; Neurology; Participant; Pathway interactions; Patients; Performance; Phase; Phenotype; Pilot Projects; Positioning Attribute; Prevention strategy; Process; Public Health Schools; Recruitment Activity; Research; Research Infrastructure; Research Personnel; Resource Sharing; Resources; Role; Sampling; Science; Scientist; Signs and Symptoms; Slide; Specimen; Staging; Study Section; Symptoms; System; Systems Biology; Techniques; Testing; Training; Transgenic Mice; Update; Ursidae Family; Woman; amyloid imaging; base; brain tissue; data management; design; disease phenotype; entorhinal cortex; genome wide association study; innovation; medical schools; mouse model; multidisciplinary; neuroimaging; neuropathology; new technology; next generation; novel strategies; open source; outreach; programs; relating to nervous system; repository; statistics; tomography; white matter

DESCRIPTION (provided by applicant): The Massachusetts Alzheimer's Disease Research Center, established in 1984, proposes to continue and expand its research into the underpinnings of Alzheimer's and related dementias with 5 major goals. First, we will focus on the earliest stages of the disease process, when symptoms and signs are subtle, or even undetectable, by bringing to bear an integrated multidisciplinary team of clinicians and scientists. Second, we will continue to provide critical infrastructure and resources to support Alzheimer disease and dementia related research across a range of institutions including Massachusetts General Hospital, Brigham and Women's Hospital, Harvard Medical School, and the Harvard School of Public Health as well as supporting national initiatives. Third, we will innovate with technical developmental projects in each Core, targeting the boundaries of cognitive ageing and disease. Fourth, we are committed to mentoring, educating, and developing future leaders through formal training or mentoring programs in each Core. Fifth, we continue to reach out to the surrounding community in order to communicate the urgency of understanding this devastating disease, and to enhance recruitment of a diverse pool of subjects and patients for critical studies. These broad aims are distributed among the mandated Administration, Clinical, Data Management and Statistics, Neuropathology and Outreach Cores, along with a new Neuroimaging Core. Each Core provides support for, and helps catalyze, the MADRC's mission, including active participation in national programs (e.g. NACC, ADNI, ADCS, ADGC, DIAN), more than 40 local clinical initiatives, and pilot projects. Three small R01 style projects leverage these Cores and are designed to marry cutting edge science with the clinical programs. Project 1, led by a new junior investigator, Dr Hedden, uses state-of-the art fMRI and Connectome techniques (a new technology that illuminates white matter pathways) as well as quantitative structural MRI approaches to study the neural system basis of the earliest cognitive impairments. Project 2, led by Dr Gomez-Isla (a senior investigator recruited to our Center in the current grant period) combines resources with 5 other ADCs to define the neuropathological phenotype of individuals who are amyloid imaging-positive and cognitively normal. Project 3, led by Dr Hyman, explores a new transgenic mouse model of Alzheimer disease that develops tangles in entorhinal cortex and widespread plaques and compares it to human neuropathological samples - to examine experimentally the neural system biology of this early point in the disease process. Together these efforts are aimed at targeting early disease phenotypes - as national efforts towards early intervention and prevention strategies unfold. Along with parallel ongoing multidisciplinary studies of established dementias, we believe the MADRC has made, and is well positioned to continue to make, strong contributions to Alzheimer research.

描述（由申请人提供）：1984年成立的马萨诸塞州阿尔茨海默氏病研究中心提议继续并将其研究扩展到阿尔茨海默氏症和相关痴呆症的基础上，并具有5​​个主要目标。首先，我们将重点关注疾病过程的最早阶段，当症状和体征是微妙甚至无法检测到的，通过带来一个综合的临床医生和科学家的多学科团队。其次，我们将继续提供关键的基础设施和资源，以支持马萨诸塞州综合医院，杨百翰和妇女医院，哈佛医学院以及哈佛大学公共卫生学院以及支持国家倡议等一系列机构的阿尔茨海默氏病和痴呆相关研究。第三，我们将通过每个核心的技术发展项目进行创新，以针对认知衰老和疾病的边界。第四，我们致力于通过每个核心中的正规培训或指导计划来指导，教育和发展未来的领导者。第五，我们继续与周围的社区接触，以传达理解这种毁灭性疾病的紧迫性，并加强招募各种受试者和患者进行批判性研究。这些广泛的目标分布在强制管理，临床，数据管理和统计，神经病理学和外展内核以及新的神经成像核心中。每个核心都为马德克的使命提供支持并帮助催化催化，包括积极参与国家计划（例如NACC，ADNI，ADCS，ADGS，ADGC，DIAN），40多个本地临床计划和试点项目。三个小型R01样式项目利用这些核心，旨在将尖端科学与临床计划结合。项目1由新的初级研究员Hedden博士领导，使用最先进的fMRI和Connectome技术（一种照亮白质途径的新技术）以及定量的结构MRI方法来研究最早认知障碍的神经系统基础。项目2由戈麦斯·伊斯兰（Gomez-Isla）博士（在当前赠款期间招募到我们的中心）与其他5个ADC相结合，以定义淀粉样蛋白成像阳性和认知正常的个体的神经病理表型。由Hyman博士领导的项目3探讨了一种新的阿尔茨海默氏病的转基因小鼠模型，该模型发展了内河皮层中的缠结和广泛的斑块，并将其与人类神经病理学样本进行了比较，以实验研究疾病过程中这种早期点的神经系统生物学。这些努力旨在针对早期疾病表型 - 随着国家为早期干预和预防策略的努力而进行。除了对已建立痴呆症的持续跨学科研究，我们认为Madrc已经做出了并且有能力继续做出的，对阿尔茨海默氏症研究做出了巨大贡献。